MOMENTUM
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients’ survival, local, and regional tumor control and quality of life (NCT04075305).
Led by UMC Utrecht, research centers across Europe, the UK, North America, and Australia joined forces to gather evidence about the effectiveness of MRgRT. The partnership has collected data from over 6,000 cancer patients, including medical images, treatment details, and information about treatment outcomes. All patients have given their permission for their data to be used in research.
MOMENTUM-AI
As the database grew to more than 15 terabytes of information, there was an exciting new opportunity: artificial intelligence could potentially interpret this wealth of data beyond current human capabilities. This insight led to MOMENTUM-AI, which aims to use AI to optimize and personalize radiation treatments. The project explores how AI can help:
- Accelerate treatment planning and delivery
- Create personalized treatment approaches
- Predict optimal treatment strategies
- Improve patient outcomes through better survival rates and reduced side effects
The long-term vision is to develop a comprehensive platform where AI supports evidence-based decision-making in radiation therapy, leading to more precise and efficient cancer treatments worldwide.
Related work
- de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, et al. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol. 2020;10:1328. Published 2020 Sep 7.
- de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, et al. Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. Int J Radiat Oncol Biol Phys. 2021;111(4):867-875.
- Daamen LA, de Mol van Otterloo SR, van Goor IWJM, et al. Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac. Acta Oncol. 2022;61(1):111-115.
- Teunissen FR, Willigenburg T, Tree AC, et al. Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. Pract Radiat Oncol. 2023;13(3):e261-e269.
- Eijkelenkamp H, Grimbergen G, Daamen LA, et al. Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac. Front Oncol. 2023;13:1040673. Published 2023 Oct 3.
- Daamen LA, Westerhoff JM, Couwenberg AM, et al. Quality of life and clinical outcomes in rectal cancer patients treated on a 1.5T MR-Linac within the MOMENTUM study. Clin Transl Radiat Oncol. 2024;45:100721. Published 2024 Jan 4.
- Sritharan K, Daamen L, Pathmanathan A, et al. MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study. Clin Transl Radiat Oncol. 2024;46:100742. Published 2024 Feb 7.
- Westerhoff JM, Daamen LA, Christodouleas JP, et al. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy. JAMA Netw Open. 2024;7(5):e2410819. Published 2024 May 1.
- Westerhoff JM, Borman PTS, Rutgers RHA, et al. On Patient Experience and Anxiety During Treatment With Magnetic Resonance-Guided Radiation Therapy. Adv Radiat Oncol. 2024;9(8):101537. Published 2024 May 4.
People
Lenny Verkooijen
Lois Daamen
